Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide followed by zoledronic acid for adults with osteogenesis imperfecta
NL-OMON59540Phase 4Completed
- Sponsor
- University of Edinburgh
- Start
- Nov 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of teriparatide and zoledronic acid in osteogenesis imperfecta (OI) (2 arms), sponsored by University of Edinburgh. Primary endpoint: Proportion of participants with imaging-confirmed clinical fracture. Started Nov 2021; status: completed.
02
Drugs
teriparatidezoledronic acid
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NL-OMON59540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59540.